Lived experiences of women reporting fatigue during PARP inhibitor maintenance treatment for advanced ovarian cancer: A qualitative study - Gynecologic Oncology
Large-scale phenotypic drug screen identifies neuroprotectants in zebrafish and mouse models of retinitis pigmentosa
Evelien SMITS, Full Professor, PhD
Potential Therapeutic Targets in Ovarian Cancer: Autophagy and Metabolism
Non‐coding RNA‐associated competitive endogenous RNA regulatory networks: Novel diagnostic and therapeutic opportunities for hepatocellular carcinoma - Khashkhashi Moghadam - 2022 - Journal of Cellular and Molecular Medicine - Wiley Online Library
Marlies VERSCHUUREN, PhD Student
beta Actin Polyclonal Antibody (20536-1-AP)
PDF) Auranofin Synergizes with the PARP Inhibitor Olaparib to
Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer. - Abstract - Europe PMC
Filip LARDON Full professor & Head research lab Center for
PDF) Auranofin Synergizes with the PARP Inhibitor Olaparib to
ASCO GU 2023: Final Overall Survival in PROpel: Abiraterone and Olaparib Versus Abiraterone and Placebo as First-Line Therapy for mCRPC
Marlies VERSCHUUREN, PhD Student
SEC Filing - Mersana Therapeutics
